LADENBURG, Germany - () - September 23, 2024 - Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today announces that new data from its ...

Blood cancers account for about 10 percent of new cancer cases each year. While the cause for most is unknown, research and treatments are improving rapidly.

The 21st annual meeting of the International Myeloma Society takes place September 25-28, 2024, in Rio de Janiero, Brazil.

The Food and Drug Administration (FDA) has approved Sarclisa ® (isatuximab-irfc) in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of patients with newly diagnosed ...

In addition to other MM indications, Isatuximab's anti-CD38 competitor on the US market, daratumumab (Darzalex — Johnson & Johnson), also carries a first-line indication for transplant-ineligible MM ...

A nurse practitioner discusses her role in caring for patients with multiple myeloma, and how advanced practice providers ...

A Boulder woman is opening up about her fight with multiple myeloma during Blood Cancer Awareness Month. She went from being ...

19, 2024. After a long battle with Multiple Myeloma, he passed away at home, surrounded by his family. He was born on May 3, 1949, in Conway, Ark., to John Thurman, Sr. and Emma Lou Starkey Tyler.

Sanofi said the Food and Drug Administration has approved Sarclisa as a first line combined treatment option for adult patients with newly diagnosed multiple myeloma who aren't eligible for autologous ...

"Cancer changes some things, of that there is no doubt. And, some things it takes away. Yet, at the same time, cancer can give." That's one of the life lessons former Pleasanton resident Ray Hartjen ...

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...